Researchers continue to excited about the medication , a novel dual agonist showing significant data in initial trials for body loss . It functions by targeting two pathways : GLP-1 and GIP, which , when https://nicoleqeiz228536.blogpostie.com/61997546/a-new-prospect-for-size-reduction